omeprazole has been researched along with clopidogrel in 109 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 19 (17.43) | 29.6817 |
2010's | 83 (76.15) | 24.3611 |
2020's | 7 (6.42) | 2.80 |
Authors | Studies |
---|---|
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Chang, CM; Chen, WH; Ng, FH; Wong, BC; Wong, SY | 1 |
Cryer, B | 1 |
Abgrall, JF; Arnaud, B; Boschat, J; Gilard, M; Le Gal, G | 1 |
Arnesen, Ø; Riis, JS | 1 |
Abgrall, JF; Arnaud, B; Boschat, J; Cornily, JC; Gilard, M; Lacut, K; Le Calvez, G; Le Gal, G; Mansourati, J; Mottier, D | 1 |
Gurbel, PA; Lau, WC; Tantry, US | 1 |
Christ, G; Jilma, B; Kreiner, G; Lang, IM; Siller-Matula, JM; Spiel, AO | 1 |
Goto, S; Serebruany, V | 1 |
Braun, S; Hadamitzky, M; Kastrati, A; Morath, T; Schömig, A; Sibbing, D; Stegherr, J; Vogt, W; von Beckerath, N | 1 |
Chen, BL; Chen, Y; Fan, L; Hu, DL; Li, Q; Li, YL; Ouyang, DS; Tan, ZR; Tu, JH; Wang, D; Wang, LS; Zhang, W; Zhou, HH | 1 |
Bouman, HJ; Taubert, D; van Werkum, JW | 1 |
Bredenoord, AJ; ten Berg, JM; van Werkum, JW | 1 |
Mathews, KD; Norgard, NB; Wall, GC | 1 |
Friesen, MH | 1 |
Mihoubi, A; Tho, A | 1 |
Alessi, MC; Bali, L; Bonnet, JL; Brissy, O; Cuisset, T; Frere, C; Gaborit, B; Morange, PE; Poyet, R; Quilici, J | 1 |
Farid, NA; Hagihara, K; Ikeda, T; Ishizuka, T; Kazui, M; Kurihara, A; Nishiya, Y; Okazaki, O | 1 |
Hennekens, C; Laine, L | 1 |
Bretagne, JF | 1 |
Herszényi, L; Juhász, M; Tulassay, Z | 1 |
Bhatt, DL; Depta, JP | 1 |
Jeong, JW; Kim, NH; Oh, SK; Park, HY; Rhee, SJ; Yoo, NJ; Yun, KH | 1 |
Adamopoulou, EN; Argyrakis, SK; Fakiolas, CN; Foussas, SG; Georgilas, AT; Kontos, CF; Patsourakos, NG; Tsiaousis, GZ; Vogiatzidis, K; Zairis, MN | 1 |
Andrén, L; Wall, U | 1 |
Chua, D; Jung, J; Lo, A | 1 |
Börgel, J; Endres, HG; Engelhardt, A; Krüger, JC; Lask, S; Mügge, A; Neubauer, H | 1 |
Alkhatib, AA; Elkhatib, FA; Khatib, OF | 1 |
Bottheim, H; Gross, M; Holinski-Feder, E; Kenngott, S; Kollmer, M; Laner, A; Olze, R | 1 |
Nathisuwan, S; Panomvana, D; Sansanayudh, N; Siriswangvat, S | 1 |
Angiolillo, DJ; Bergougnan, L; Cheng, S; Dubar, M; Gibson, CM; Hurbin, F; LaCreta, FP; Nicolas, O; Ollier, C; Perrin, L | 1 |
Angiolillo, DJ; Bass, TA; Capodanno, D; Charlton, RK; Darlington, A; Desai, B; Dharmashankar, K; Ferreiro, JL; Ueno, M | 1 |
Bhatt, DL; Cannon, CP; Cohen, M; Contant, CF; Cryer, BL; Goldsmith, MA; Laine, L; Lanas, A; Lapuerta, P; Murphy, SA; Schnitzer, TJ; Scirica, BM; Shook, TL | 1 |
Pai, RG; Tafreshi, J; Tran, M | 1 |
Kandulski, A; Malfertheiner, P; Venerito, M | 1 |
Cai, J; Fan, L; Liu, CF; Sun, J; Wang, ZG; Wu, Q | 1 |
Southworth, MR; Temple, R | 1 |
Danikiewicz, A; Hudzik, B; Lekston, A; Polonski, L; Romanowski, W; Szkodzinski, J; Wilczek, K; Zubelewicz-Szkodzinska, B | 1 |
Vassiliou, V | 1 |
Laine, L | 1 |
Juurlink, DN | 1 |
Ford, AC; Sadek, A | 1 |
Giraldo-Giraldo, C; Machado-Alba, JE; Moncada-Escobar, JC | 1 |
Chyrchel, B; Chyrchel, M; Dubiel, JS; Dudek, D; Surdacki, A | 1 |
Boura, J; Harjai, KJ; Mehta, RH; Orshaw, P; Shenoy, C; Usmani, S | 1 |
Hiraishi, H; Kanke, K; Maeda, M; Sasai, T; Shimada, T | 1 |
Albuquerque, A; Araújo, C; Fontes-Carvalho, R; Pimentel-Nunes, P; Ribeiro, VG | 1 |
Chen, JS; Chen, L; Chen, YD; Guo, YS; Huang, TT; Liu, HB; Ren, YH; Sun, ZJ; Wang, CY; Wang, Y; Xie, YJ; Zhao, M | 1 |
Keller, DL | 1 |
Boot, H; de Boer, A; Deneer, VH; Harmsze, AM; Heringa, M; le Comte, M; Mol, PG; Schalekamp, T; Verduijn, MM; Verheugt, FW | 1 |
Buckley, DB; Kazmi, F; Ogilvie, BW; Paris, BL; Parkinson, A; Rostami-Hodjegan, A; Toren, P; Yerino, P | 1 |
Htun, WW; Huang, Y; Ko, W; Kwan, J; Kwan, TW | 1 |
Chen, PF; Hsiao, FY; Huang, WF; Mullins, CD; Tsai, YW; Wen, YW | 1 |
Amariles, P; Ceballos, M; Holguín, H | 1 |
Abraham, NS | 1 |
Boulenc, X; Brian, W; Djebli, N; Hurbin, F; Perrin, L; Shi, J; Van Horn, R | 1 |
Gammack, JK; Messinger-Rapport, BJ; Morley, JE; Thomas, DR | 1 |
Antonino, M; Bliden, KP; Fort, J; Gesheff, M; Gurbel, PA; Plachetka, JR; Tantry, US; Zhang, Y | 1 |
Harrison, RW; Mahaffey, KW | 1 |
Azab, AN; Friger, M; Gilutz, H; Shmulevich, E | 1 |
Kwok, CS; Loke, YK | 1 |
Chen, J; Howden, CW; Leontiadis, GI; Yuan, YC | 1 |
Hashimoto, E; Izuhara, C; Kaneko, S; Takayama, S; Takeuchi, K; Yamada, N; Yamanaka, S | 1 |
Bhatt, DL; Brooks, JK; Frelinger, AL; Lee, RD; Michelson, AD; Mulford, DJ; Nigam, A; Nudurupati, S; Wu, J | 1 |
Horiuchi, H; Ikeda, T; Imai, M; Jinnai, T; Kato, Y; Kimura, T; Makiyama, T; Shirakawa, R; Tada, T; Tazaki, J; Yamane, K | 1 |
Endo, T; Fukui, K; Hibi, K; Himeno, H; Kimura, K; Morita, S; Sugano, T; Tsukahara, K; Umemura, S; Yano, H | 1 |
Lu, FM; Mao, YM; Tong, ZL; Wu, DY; Xu, J | 1 |
Horiuchi, H | 1 |
Chen, YF; Dang, DS; Liu, Q; Shi, GB; Yan, M; Zhao, QC | 1 |
Duh, D; Tanret, I | 1 |
Antonino, M; Bliden, KP; Chai, S; Fort, JG; Gesheff, M; Gesheff, T; Gurbel, PA; Jeong, YH; Shuldiner, A; Tantry, US; Zhang, Y | 1 |
Banahan, BF; Bentley, JP; Datar, MV; Mahabaleshwarkar, RK; Null, KD; Strum, MW; Yang, Y | 1 |
Abramowitz, Y; Arbel, Y; Banai, S; Berliner, S; Birati, EY; Deutsch, V; Finkelstein, A; Halkin, A; Herz, I; Keren, G; Kletzel, H | 1 |
Coleman, JJ; Dhami, A; Hodson, J; McIlroy, G; Thomas, SK | 1 |
D'Ugo, E; De Caterina, R; Rossi, S | 1 |
Azizi, M; Ducint, D; Funck-Brentano, C; Gaussem, P; Molimard, M; Remones, V; Steichen, O; Szymezak, J | 1 |
Juurlink, D | 1 |
Bhatt, DL | 1 |
Chen, G; Du, Y; Hang, L; Ma, B | 1 |
Amariles, P; Angulo, NY; Betancourth, PM; Ceballos, M; Holguín, H | 1 |
Al-Tannir, M; Bahamid, R; Kashour, T | 1 |
Antoku, Y; Hanatani, T; Hori, K; Kawakami, J; Kimura, M; Nakashima, N; Ohe, K; Sai, K; Saito, Y; Segawa, K; Tohkin, M; Yokoi, H | 1 |
Andersson, T; Galbraith, H; Nagy, P; Niazi, M; Nylander, S; Ranjan, S; Wallentin, L | 1 |
El Rouby, N; Goldstein, JA; Johnson, JA; Langaee, TY; Markowitz, JS; Wang, X; Zhu, HJ | 1 |
Bertino, JS | 1 |
Bilker, WB; Brensinger, CM; Flockhart, DA; Freeman, CP; Hennessy, S; Kasner, SE; Kimmel, SE; Leonard, CE | 1 |
Bhatt, DL; Cannon, CP; Cohen, M; Cryer, BL; Doros, G; Goldsmith, MA; Laine, L; Lanas, A; Lapuerta, P; Liu, Y; McIntosh, AI; Schnitzer, TJ; Vardi, M | 1 |
Cayla, G; Collet, JP; Finzi, J; Hulot, JS; Montalescot, G; Simon, N | 1 |
Ford, NF | 1 |
Barbeau, G; Bertrand, OF; De Larochellière, R; Déry, JP; Déry, U; Gleeton, O; Harvey, A; Larose, É; Modak, A; Nguyen, CM; Noël, B; Paradis, JM; Proulx, G; Rinfret, S; Rodés-Cabau, J; Roy, L; Roy, M | 1 |
Bhatt, DL; Cannon, CP; Cohen, M; Cryer, BL; Doros, G; Goldsmith, MA; Hsieh, WH; Laine, L; Lanas, A; Lapuerta, P; Liu, Y; Schnitzer, TJ; Shook, TL; Vaduganathan, M | 2 |
D'Amico, EA; Filho, CC; Filho, RK; Freire, BT; Furtado, RHM; Giugliano, RP; Neto, PAL; Nicolau, JC; Pereira, AC; Ramires, JAF; Rocha, TR; Strunz, CMC | 1 |
Fort, JG; Han, Y; Schofield, D; Tursi, JP; Zhang, W | 1 |
Kruik, HJ; Kruik-Kollöffel, WJ; Movig, KLL; van der Palen, J; van Herk-Sukel, MPP | 1 |
Lohitnavy, M; Lohitnavy, O; Morasuk, T; Tangamornsuksan, W; Thiansupornpong, P | 1 |
Jirungda, S; Komanasin, N; Leuangwatthananon, W; Pussadhamma, B; Senthong, V | 1 |
Munthe, DHB; Sargo, SS; Yogiarto, M | 1 |
Chan, MY; Chew, NWS; Dan, YY; Foo, LL; Ho, KY; Lee, CH; Lim, LG; Low, AF; Muthiah, MD; Richards, AM; Tan, HC; Xiao, J; Yip, JWL; Zheng, H | 1 |
Albuquerque, FC; Baranoski, JF; Catapano, JS; Cole, TS; Ducruet, AF; Fredrickson, VL; Lundberg, JN; Rahmani, R; Rutledge, C; Srinivasan, VM; Wakim, AA | 1 |
Cao, X; Chen, C; Chen, L; Liu, Y; Miao, Y; Niu, J; Sun, Y; Wei, J; Wu, T; Xu, Z | 1 |
Denda, M; Goda, M; Hamano, H; Higashionna, T; Ishizawa, K; Lin, TJ; Miyata, K; Nawa, H; Neishi, M; Niimura, T; Yagi, K; Zamami, Y | 1 |
Häyrynen, S; Kiiski, JI; Niemi, M; Ramste, M; Ritvos, M; Sinisalo, J | 1 |
17 review(s) available for omeprazole and clopidogrel
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Drug-drug interaction between clopidogrel and the proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Clinical Trials as Topic; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Humans; Omeprazole; Pantoprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Ticlopidine | 2009 |
Proton pump inhibitor and clopidogrel interaction: fact or fiction?
Topics: Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Humans; Omeprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Risk Factors; Ticlopidine | 2010 |
[Prevention of GI bleeding due to antiplatelet agents: a labyrinth!].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Humans; Lansoprazole; Omeprazole; Pantoprazole; Platelet Aggregation; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Risk Factors; Ticlopidine | 2009 |
Current standings of the proton pump inhibitor and clopidogrel co-therapy: review on an evolving field with the eyes of the gastroenterologist.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Gastroenterology; Gastrointestinal Hemorrhage; Humans; Myocardial Infarction; Omeprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Recurrence; Ticlopidine | 2010 |
Review article: combination of clopidogrel and proton pump inhibitors: implications for clinicians.
Topics: Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Therapy, Combination; Humans; Myocardial Infarction; Omeprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Risk Factors; Stroke; Ticlopidine; Treatment Outcome | 2010 |
[Dilemma between gastroprotection and cardiovascular prevention].
Topics: Alleles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Drug-Eluting Stents; Humans; Long-Term Care; Mutation; Omeprazole; Peptic Ulcer Hemorrhage; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Survival Analysis; Ticlopidine; Treatment Outcome | 2010 |
[Strategy to manage low dose aspirin-induced gastrointestinal injury].
Topics: Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Clopidogrel; Famotidine; Gastric Mucosa; Humans; Omeprazole; Peptic Ulcer; Platelet Aggregation Inhibitors; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Proton Pump Inhibitors; Ticlopidine | 2011 |
[Interaction between clopidogrel and proton pump inhibitors].
Topics: Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Therapy, Combination; Esomeprazole; Gastrointestinal Hemorrhage; Humans; Omeprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Ticlopidine | 2011 |
Prescribing proton pump inhibitor and clopidogrel together: current state of recommendations.
Topics: Clopidogrel; Drug Interactions; Drug Prescriptions; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Humans; Omeprazole; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Proton Pump Inhibitors; Risk Assessment; Risk Factors; Ticlopidine | 2011 |
Clopidogrel and PPI interaction: clinically relevant or not?
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Female; Gastrointestinal Hemorrhage; Humans; Male; Omeprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Thienopyridines; Ticlopidine | 2012 |
Clopidogrel and proton pump inhibitors: is there a significant drug-drug interaction?
Topics: Clopidogrel; Drug Interactions; Drug Therapy, Combination; Humans; Omeprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Ticlopidine | 2011 |
Effects of proton pump inhibitors on platelet function in patients receiving clopidogrel: a systematic review.
Topics: Blood Platelets; Clopidogrel; Drug Interactions; Esomeprazole; Humans; Omeprazole; Platelet Aggregation; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Ticlopidine | 2012 |
Recent safety concerns with proton pump inhibitors.
Topics: Clopidogrel; Drug Interactions; Drug Therapy, Combination; Fractures, Spontaneous; Gastrointestinal Hemorrhage; Humans; Hypercalciuria; Nephrocalcinosis; Omeprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Renal Tubular Transport, Inborn Errors; Risk Factors; Ticlopidine; Treatment Outcome | 2012 |
Proton pump inhibitors and clopidogrel: an association to avoid?
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Humans; Lansoprazole; Monitoring, Physiologic; Omeprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Ticlopidine | 2014 |
Clopidogrel and Genotyping.
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Genotype; Humans; Omeprazole; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Risk Factors; Stents; Ticlopidine | 2015 |
Outcomes of a multi-ethnic Asian population on combined treatment with clopidogrel and omeprazole in 12,440 patients.
Topics: Asian People; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Ethnicity; Humans; Myocardial Infarction; Omeprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Retrospective Studies; Stroke; Ticlopidine | 2021 |
31 trial(s) available for omeprazole and clopidogrel
Article | Year |
---|---|
Clopidogrel plus omeprazole compared with aspirin plus omeprazole for aspirin-induced symptomatic peptic ulcers/erosions with low to moderate bleeding/re-bleeding risk -- a single-blind, randomized controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Aspirin; Clopidogrel; Female; Humans; Male; Middle Aged; Omeprazole; Peptic Ulcer; Peptic Ulcer Hemorrhage; Risk Factors; Single-Blind Method; Ticlopidine | 2004 |
Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Cell Adhesion Molecules; Clopidogrel; Double-Blind Method; Drug Antagonism; Drug Therapy, Combination; Female; Humans; Male; Microfilament Proteins; Middle Aged; Myocardial Infarction; Omeprazole; Phosphoproteins; Phosphorylation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Proton Pump Inhibitors; Stents; Ticlopidine | 2008 |
Clopidogrel inhibits CYP2C19-dependent hydroxylation of omeprazole related to CYP2C19 genetic polymorphisms.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Chromatography, High Pressure Liquid; Clopidogrel; Cross-Over Studies; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Therapy, Combination; Genotype; Humans; Hydroxylation; Male; Omeprazole; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Spectrophotometry, Ultraviolet; Sulfoxides; Ticlopidine; Young Adult | 2009 |
Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Anti-Ulcer Agents; Clopidogrel; Drug Interactions; Female; Humans; Male; Middle Aged; Omeprazole; Pantoprazole; Platelet Aggregation Inhibitors; Prospective Studies; Proton Pump Inhibitors; Stents; Ticlopidine | 2009 |
Effects of omeprazole on the antiplatelet activity of clopidogrel.
Topics: Adult; Anti-Ulcer Agents; Blood Platelets; Clopidogrel; Cross-Over Studies; Drug Interactions; Female; Humans; Male; Omeprazole; Platelet Aggregation Inhibitors; Ticlopidine | 2010 |
Pantoprazole does not influence the antiplatelet effect of clopidogrel-a whole blood aggregometry study after coronary stenting.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Interactions; Esomeprazole; Female; Humans; Male; Middle Aged; Multivariate Analysis; Omeprazole; Pantoprazole; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Proton Pump Inhibitors; Regression Analysis; Stents; Ticlopidine | 2010 |
Comparison between the effect of omeprazole and rabeprazole on the antiplatelet action of clopidogrel.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Diphosphate; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Interactions; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Omeprazole; Platelet Aggregation; Platelet Aggregation Inhibitors; Rabeprazole; Ticlopidine; Treatment Outcome | 2010 |
Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cross-Over Studies; Cytochrome P-450 CYP2C19; Double-Blind Method; Drug Administration Schedule; Drug Interactions; Enzyme Inhibitors; Female; Half-Life; Humans; Male; Middle Aged; Omeprazole; Pantoprazole; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prodrugs; Proton Pump Inhibitors; Ticlopidine; Young Adult | 2011 |
Pharmacodynamic effects of concomitant versus staggered clopidogrel and omeprazole intake: results of a prospective randomized crossover study.
Topics: Adult; Clinical Protocols; Clopidogrel; Drug Incompatibility; Drug Interactions; Female; Humans; Male; Omeprazole; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2010 |
Clopidogrel with or without omeprazole in coronary artery disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Interactions; Drug Therapy, Combination; Female; Gastrointestinal Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Omeprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Ticlopidine | 2010 |
[Impact of different proton pump inhibitors on the antiplatelet activity of clopidogrel in combination with aspirin for patients undergoing coronary stent implantation].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Angioplasty, Balloon; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Omeprazole; Pantoprazole; Platelet Aggregation; Postoperative Period; Proton Pump Inhibitors; Stents; Ticlopidine | 2010 |
Effect of omeprazole on the concentration of interleukin-6 and transforming growth factor-β1 in patients receiving dual antiplatelet therapy after percutaneous coronary intervention.
Topics: Aged; Anti-Ulcer Agents; Aspirin; Biomarkers; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, Combination; Female; Follow-Up Studies; Gene Expression Regulation; Humans; Interleukin-6; Male; Middle Aged; Omeprazole; Platelet Aggregation Inhibitors; Predictive Value of Tests; Ticlopidine; Transforming Growth Factor beta1; Treatment Outcome | 2010 |
Separate dosing of clopidogrel and omeprazole may improve platelet inhibition on dual antiplatelet therapy.
Topics: Aged; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Omeprazole; Pilot Projects; Platelet Activation; Platelet Aggregation Inhibitors; Ticlopidine | 2011 |
Omeprazole, but not pantoprazole, reduces the antiplatelet effect of clopidogrel: a randomized clinical crossover trial in patients after myocardial infarction evaluating the clopidogrel-PPIs drug interaction.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Blood Platelets; Clopidogrel; Cross-Over Studies; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Omeprazole; Pantoprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Ticlopidine | 2011 |
Omeprazole affects clopidogrel efficacy but not ischemic events in patients with acute coronary syndrome undergoing elective percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; Humans; Male; Middle Aged; Omeprazole; Platelet Aggregation Inhibitors; Ticlopidine | 2011 |
Effects of omeprazole and genetic polymorphism of CYP2C19 on the clopidogrel active metabolite.
Topics: Adolescent; Adult; Aged; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cross-Over Studies; Cytochrome P-450 CYP2C19; Female; Humans; Male; Microsomes, Liver; Middle Aged; Omeprazole; Polymorphism, Genetic; Ticlopidine | 2012 |
Pharmacodynamic evaluation of clopidogrel plus PA32540: the Spaced PA32540 With Clopidogrel Interaction Gauging (SPACING) study.
Topics: Adult; Anti-Ulcer Agents; Aspirin; Clopidogrel; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Interactions; Female; Humans; Least-Squares Analysis; Male; Omeprazole; Platelet Aggregation Inhibitors; Tablets, Enteric-Coated; Ticlopidine | 2011 |
A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Area Under Curve; Blood Coagulation; Blood Platelets; Clopidogrel; Confidence Intervals; Cross-Over Studies; Dexlansoprazole; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Esomeprazole; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Reference Values; Ticlopidine; Young Adult | 2012 |
Influence of omeprazole and famotidine on the antiplatelet effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes: a prospective, randomized, multicenter study.
Topics: Acute Coronary Syndrome; Aged; Anti-Ulcer Agents; Aspirin; Blood Platelets; Clopidogrel; Drug Antagonism; Famotidine; Female; Humans; Male; Middle Aged; Myocardial Infarction; Omeprazole; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticlopidine | 2012 |
The influence of omeprazole on platelet inhibition of clopidogrel in various CYP2C19 mutant alleles.
Topics: Alleles; Aryl Hydrocarbon Hydroxylases; Aspirin; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Humans; Male; Omeprazole; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine; Young Adult | 2012 |
Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel.
Topics: Administration, Oral; Adult; Aspirin; Clopidogrel; Coronary Thrombosis; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Follow-Up Studies; Gastrointestinal Diseases; Humans; Middle Aged; Omeprazole; Platelet Aggregation; Platelet Aggregation Inhibitors; Tablets, Enteric-Coated; Ticlopidine; Treatment Outcome | 2013 |
Platelet inhibitory effect of clopidogrel in patients treated with omeprazole, pantoprazole, and famotidine: a prospective, randomized, crossover study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Aspirin; Chi-Square Distribution; Clopidogrel; Cross-Over Studies; Drug Interactions; Drug Resistance; Drug Therapy, Combination; Famotidine; Female; Histamine H2 Antagonists; Humans; Israel; Linear Models; Male; Middle Aged; Omeprazole; Pantoprazole; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Proton Pump Inhibitors; Single-Blind Method; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers.
Topics: Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Biotransformation; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Cross-Over Studies; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Drug Interactions; Enzyme Inhibitors; Half-Life; Healthy Volunteers; Humans; Male; Metabolic Clearance Rate; Microfilament Proteins; Omeprazole; Paris; Phosphoproteins; Phosphorylation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Ticlopidine | 2013 |
Effect of clopidogrel with or without omeprazole in patients with carotid artery stenting.
Topics: Angiography; Aspirin; Breath Tests; Carotid Arteries; Carotid Stenosis; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Female; Gastrointestinal Hemorrhage; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Peptic Ulcer; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Stents; Ticlopidine | 2013 |
Effect of esomeprazole with/without acetylsalicylic acid, omeprazole and lansoprazole on pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
Topics: Adolescent; Adult; Area Under Curve; Aspirin; Clopidogrel; Cross-Over Studies; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Esomeprazole; Female; Healthy Volunteers; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Platelet Aggregation; Proton Pump Inhibitors; Ticlopidine; Young Adult | 2014 |
The effects of proton pump inhibition on patient-reported severity of dyspepsia when receiving dual anti-platelet therapy with clopidogrel and low-dose aspirin: analysis from the Clopidogrel and the Optimization of Gastrointestinal Events Trial.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Dyspepsia; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Omeprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Ticlopidine; Young Adult | 2015 |
Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Alleles; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Interactions; Female; Genotype; Humans; Male; Middle Aged; Models, Biological; Omeprazole; Pantoprazole; Platelet Aggregation; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Ticlopidine | 2015 |
Changes in CYP2C19 enzyme activity evaluated by the [(13)C]-pantoprazole breath test after co-administration of clopidogrel and proton pump inhibitors following percutaneous coronary intervention and correlation to platelet reactivity.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Blood Platelets; Breath Tests; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Esomeprazole; Humans; Omeprazole; Pantoprazole; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Proton Pump Inhibitors; Ranitidine; Ticlopidine | 2016 |
Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy.
Topics: Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyspepsia; Female; Gastrointestinal Hemorrhage; Humans; Intestinal Obstruction; Intestinal Perforation; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Omeprazole; Pain; Peptic Ulcer; Platelet Aggregation Inhibitors; Prospective Studies; Proton Pump Inhibitors; Stroke; Ticlopidine | 2016 |
Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Humans; Omeprazole; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Ticlopidine; Treatment Outcome | 2016 |
Drug Interaction Between Clopidogrel and Ranitidine or Omeprazole in Stable Coronary Artery Disease: A Double-Blind, Double Dummy, Randomized Study.
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Omeprazole; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Proton Pump Inhibitors; Ranitidine; Ticlopidine | 2016 |
61 other study(ies) available for omeprazole and clopidogrel
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Reducing the risks of gastrointestinal bleeding with antiplatelet therapies.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Humans; Omeprazole; Peptic Ulcer Hemorrhage; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Ticlopidine | 2005 |
Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin.
Topics: Aged; Angioplasty; Aryl Hydrocarbon Hydroxylases; Aspirin; Cell Adhesion Molecules; Clopidogrel; Coronary Disease; Cytochrome P-450 CYP2C19; Drug Antagonism; Enzyme Inhibitors; Female; Humans; Male; Microfilament Proteins; Mixed Function Oxygenases; Omeprazole; Phosphoproteins; Phosphorylation; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Single Nucleotide; Protein Processing, Post-Translational; Thrombosis; Ticlopidine | 2006 |
[Platelet inhibition and gastric problems].
Topics: Anti-Ulcer Agents; Aspirin; Clopidogrel; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Humans; Omeprazole; Platelet Aggregation Inhibitors; Ticlopidine | 2007 |
Omeprazole: a possible new candidate influencing the antiplatelet effect of clopidogrel.
Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Antagonism; Drug Therapy, Combination; Humans; Mixed Function Oxygenases; Omeprazole; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Proton Pump Inhibitors; Stents; Ticlopidine | 2008 |
Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Blood Platelets; Clopidogrel; Drug Interactions; Esomeprazole; Female; Humans; Male; Middle Aged; Omeprazole; Pantoprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Ticlopidine | 2009 |
[Proton pump inhibition: more than only reflux therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Asthma; Chest Pain; Clopidogrel; Comorbidity; Controlled Clinical Trials as Topic; Coronary Disease; Diagnosis, Differential; Drug Therapy, Combination; Gastroesophageal Reflux; Humans; Omeprazole; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Proton Pump Inhibitors; Rabeprazole; Secondary Prevention; Ticlopidine; Time Factors | 2008 |
Clopidogrel and proton pump inhibitors: gastric protection at expense of vascular benefit?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Interactions; Drug Therapy, Combination; Humans; Omeprazole; Pantoprazole; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Proton Pump Inhibitors; Stents; Ticlopidine | 2009 |
Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Cross-Sectional Studies; Drug Interactions; Drug Therapy, Combination; Esomeprazole; Female; Humans; Male; Middle Aged; Multivariate Analysis; Omeprazole; Pantoprazole; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Proton Pump Inhibitors; Stents; Ticlopidine | 2009 |
Cytochrome P-450 polymorphisms and response to clopidogrel.
Topics: Aryl Hydrocarbon Hydroxylases; Biotransformation; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Linkage Disequilibrium; Microsomes; Omeprazole; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Ticlopidine | 2009 |
Proton pump inhibitors and clopidogrel: a difficult dilemma.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Clopidogrel; Drug Interactions; Gastrointestinal Hemorrhage; Humans; Omeprazole; Pantoprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Thrombosis; Ticlopidine | 2009 |
Interaction between clopidogrel and proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Case-Control Studies; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Humans; Lansoprazole; Myocardial Infarction; Odds Ratio; Omeprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Rabeprazole; Secondary Prevention; Ticlopidine | 2009 |
Do the association of cytochrome P450 interacting drugs, influence clopidogrel efficacity?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Blood Platelets; Clopidogrel; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Therapy; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Omeprazole; Pantoprazole; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2009 |
Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite.
Topics: Antibodies; Aryl Hydrocarbon Hydroxylases; Biocatalysis; Biotransformation; Cell Line; Cell Line, Tumor; Clopidogrel; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Glutathione; Humans; Ketoconazole; Kinetics; Mephenytoin; Microsomes; Microsomes, Liver; NADP; Omeprazole; Oxidation-Reduction; Oxidoreductases, N-Demethylating; Platelet Aggregation Inhibitors; Sulfaphenazole; Theophylline; Ticlopidine | 2010 |
Omeprazole and clopidogrel: Should clinicians be worried?
Topics: Anti-Ulcer Agents; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Humans; Omeprazole; Platelet Aggregation Inhibitors; Ticlopidine | 2010 |
The impact of treatment with omeprazole on the effectiveness of clopidogrel drug therapy during the first year after successful coronary stenting.
Topics: Administration, Oral; Angina, Unstable; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Drug Therapy, Combination; Enzyme Inhibitors; Female; Follow-Up Studies; Greece; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Omeprazole; Patient Readmission; Platelet Aggregation Inhibitors; Prospective Studies; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
[Risky to combine clopidogrel with proton pump inhibitor?].
Topics: Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Information Services; Drug Interactions; Enzyme Inhibitors; Humans; Omeprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Risk Factors; Ticlopidine | 2009 |
Evidence for interaction between clopidogrel and proton-pump inhibitors.
Topics: Clopidogrel; Controlled Clinical Trials as Topic; Drug Interactions; Humans; Omeprazole; Platelet Aggregation Inhibitors; Platelet Count; Proton Pump Inhibitors; Ticlopidine; United States; United States Food and Drug Administration | 2010 |
If I take the blood thinner Plavix, should I avoid using Prilosec or other heartburn medications?
Topics: Anti-Ulcer Agents; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Health Knowledge, Attitudes, Practice; Heartburn; Humans; Myocardial Infarction; Omeprazole; Patient Education as Topic; Platelet Aggregation Inhibitors; Risk Factors; Stroke; Ticlopidine | 2010 |
Controversial warning on Plavix and stomach-protecting medications.
Topics: Anti-Ulcer Agents; Clopidogrel; Drug Interactions; Drug Labeling; Health Knowledge, Attitudes, Practice; Humans; Omeprazole; Platelet Aggregation Inhibitors; Stomach Ulcer; Ticlopidine; United States; United States Food and Drug Administration | 2010 |
Gastric acid-reducing medications and clopidogrel: what are the latest FDA recommendations?
Topics: Anticoagulants; Clopidogrel; Drug Interactions; Endoscopy, Gastrointestinal; Female; Humans; Male; Omeprazole; Proton Pump Inhibitors; Safety Management; Thromboembolism; Ticlopidine; United States; United States Food and Drug Administration | 2010 |
Clopidogrel and proton pump inhibitor (PPI) interaction: separate intake and a non-omeprazole PPI the solution?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Female; Humans; Male; Middle Aged; Omeprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Rabeprazole; Ticlopidine | 2010 |
Interaction of clopidogrel and omeprazole.
Topics: Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Interactions; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Humans; Omeprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Ticlopidine | 2010 |
In brief: Clopidogrel and omeprazole.
Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Gastrointestinal Hemorrhage; Humans; Omeprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Ticlopidine | 2010 |
Double-dose clopidogrel in patients undergoing PCI for ACS.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Interactions; Humans; Omeprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Ticlopidine | 2011 |
Proton pump inhibitor co-therapy with clopidogrel: is there GI benefit or cardiovascular harm?
Topics: Atherosclerosis; Clopidogrel; Drug Interactions; Humans; Omeprazole; Peptic Ulcer; Platelet Aggregation; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Risk Assessment; Secondary Prevention; Ticlopidine; Time Factors; Treatment Outcome | 2011 |
Clopidogrel with or without omeprazole in coronary disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Cardiovascular Diseases; Chemistry, Pharmaceutical; Clopidogrel; Coronary Artery Disease; Drug Interactions; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Humans; Omeprazole; Pantoprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Ticlopidine | 2011 |
Clopidogrel with or without omeprazole in coronary disease.
Topics: Clopidogrel; Coronary Artery Disease; Cost-Benefit Analysis; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Humans; Omeprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Ticlopidine | 2011 |
[Active pharmacosurveillance of patients affiliated to the Colombian general social security/health system].
Topics: Adverse Drug Reaction Reporting Systems; Calcium Channel Blockers; Clopidogrel; Colombia; Diphosphonates; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Humans; Imidazoles; Losartan; Medication Systems; Metoprolol; National Health Programs; Omeprazole; Retrospective Studies; Social Security; Software; Ticlopidine; Zoledronic Acid | 2010 |
Clinical outcomes in patients with the concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention: an analysis from the Guthrie Health Off-Label Stent (GHOST) investigators.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Interactions; Female; Humans; Male; Middle Aged; Omeprazole; Platelet Aggregation Inhibitors; Proportional Hazards Models; Proton Pump Inhibitors; Stents; Ticlopidine; Treatment Outcome | 2011 |
Coadministration of clopidogrel and proton pump inhibitors.
Topics: Clopidogrel; Drug Interactions; Drug Therapy, Combination; Humans; Omeprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Ticlopidine | 2011 |
The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Drug Interactions; Enzyme Inhibitors; Esomeprazole; Hepatocytes; Humans; Inhibitory Concentration 50; Lansoprazole; Microsomes; Microsomes, Liver; Omeprazole; Pantoprazole; Protein Binding; Proton Pump Inhibitors; Recombinant Proteins; Ticlopidine | 2011 |
Effect of proton pump inhibitors on platelet inhibition activity of clopidogrel in Chinese patients with percutaneous coronary intervention.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Asian; Asian People; Blood Platelets; China; Clopidogrel; Drug Resistance; Esomeprazole; Female; Humans; Lansoprazole; Male; Middle Aged; New York City; Omeprazole; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Proton Pump Inhibitors; Stents; Thrombosis; Ticlopidine; Time Factors | 2011 |
Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Cardiovascular Diseases; Clopidogrel; Cohort Studies; Cytochrome P-450 CYP2C19; Databases, Factual; Drug Interactions; Esomeprazole; Female; Herb-Drug Interactions; Hospitalization; Humans; Male; Middle Aged; Omeprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Recurrence; Retrospective Studies; Ticlopidine; Treatment Outcome | 2011 |
[Clinical importance of the clopidogrel - omeprazole interaction: a question to solve].
Topics: Clopidogrel; Controlled Clinical Trials as Topic; Drug Interactions; Gastrointestinal Hemorrhage; Humans; Omeprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Ticlopidine | 2012 |
Clinical update on nursing home medicine: 2011.
Topics: Anti-Ulcer Agents; Anticoagulants; Atrial Fibrillation; Clopidogrel; Clostridioides difficile; Delirium; Diabetes Complications; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Female; Fractures, Bone; Geriatric Nursing; Humans; Male; Nursing Homes; Omeprazole; Osteoporosis; Peptic Ulcer; Platelet Aggregation Inhibitors; Pneumonia, Bacterial; Polypharmacy; Proton Pump Inhibitors; Risk Factors; Ticlopidine; Warfarin; Weight Loss | 2011 |
A new model of gastric bleeding induced in rats by aspirin plus clopidogrel under stimulation of acid secretion. Prophylactic effects of antiulcer drugs.
Topics: Animals; Anti-Ulcer Agents; Aspirin; Clopidogrel; Drug Interactions; Famotidine; Gastric Acid; Gastric Mucosa; Gastrointestinal Hemorrhage; Male; Omeprazole; Peroxidase; Rats; Rats, Sprague-Dawley; Stomach Ulcer; Ticlopidine | 2012 |
Effects of PPIs and an H2 blocker on the antiplatelet function of clopidogrel in Japanese patients under dual antiplatelet therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Asian People; Aspirin; Case-Control Studies; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Drug Therapy, Combination; Enzyme Inhibitors; Female; Histamine H2 Antagonists; Humans; Male; Omeprazole; Platelet Aggregation; Platelet Aggregation Inhibitors; Prognosis; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Ticlopidine | 2012 |
[Impact of proton pump inhibitor omeprazole on the antiplatelet effect of clopidogrel in individuals with various CYP2C19*2 genotypes].
Topics: Adult; Aged; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Female; Humans; Male; Middle Aged; Omeprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Ticlopidine | 2012 |
Proton-pump inhibitors could be innocent when used concomitantly with clopidogrel.
Topics: Acute Coronary Syndrome; Anti-Ulcer Agents; Aspirin; Blood Platelets; Clopidogrel; Famotidine; Female; Humans; Male; Omeprazole; Platelet Aggregation Inhibitors; Ticlopidine | 2012 |
[Comment of the Delphi Care editors on Critical evaluation of interaction screening software available in pharmacies].
Topics: Anti-Bacterial Agents; Aromatase Inhibitors; Clopidogrel; Contraceptives, Oral; Delphi Technique; Drug Interactions; Estrogens; Female; Humans; Omeprazole; Pharmacies; Pharmacists; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Software; Ticlopidine | 2012 |
Risk of adverse cardiovascular outcomes and all-cause mortality associated with concomitant use of clopidogrel and proton pump inhibitors in elderly patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Case-Control Studies; Clopidogrel; Cohort Studies; Coronary Artery Bypass; Drug Interactions; Drug Therapy, Combination; Esomeprazole; Female; Humans; Lansoprazole; Male; Myocardial Infarction; Omeprazole; Pantoprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Rabeprazole; Risk; Stroke; Ticlopidine | 2013 |
The impact of direct healthcare professional communication on prescribing practice in the UK hospital setting: an interrupted time series analysis.
Topics: Adverse Drug Reaction Reporting Systems; Antipsychotic Agents; Clopidogrel; Communication; Dementia; Drug Interactions; Drug Prescriptions; Health Personnel; Hospitals; Humans; Omeprazole; Practice Patterns, Physicians'; Proton Pump Inhibitors; Ticlopidine; United Kingdom | 2013 |
Clopidogrel and proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Coronary Syndrome; Clinical Trials as Topic; Clopidogrel; Drug Combinations; Drug Interactions; Humans; Omeprazole; Pantoprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Ticlopidine | 2014 |
Clopidogrel and proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Clopidogrel; Humans; Omeprazole; Pantoprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Ticlopidine | 2014 |
[Effect of drug interaction between clopidogrel and omeprazole in hospital readmision of patients by a recurrent acute coronary syndrome: a case-control study].
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Case-Control Studies; Clopidogrel; Drug Interactions; Female; Humans; Male; Middle Aged; Omeprazole; Patient Readmission; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Recurrence; Ticlopidine | 2014 |
Changing prescription pattern of omeprazole among patients receiving clopidogrel.
Topics: Clopidogrel; Drug Interactions; Drug Prescriptions; Drug Therapy, Combination; Follow-Up Studies; Gastrointestinal Diseases; Humans; Myocardial Ischemia; Omeprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Retrospective Studies; Ticlopidine | 2014 |
Evaluation of two Japanese regulatory actions using medical information databases: a 'Dear Doctor' letter to restrict oseltamivir use in teenagers, and label change caution against co-administration of omeprazole with clopidogrel.
Topics: Adolescent; Age Factors; Antiviral Agents; Child; Clopidogrel; Databases, Factual; Drug and Narcotic Control; Drug Interactions; Humans; Interrupted Time Series Analysis; Japan; Omeprazole; Oseltamivir; Pharmacovigilance; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Proton Pump Inhibitors; Regression Analysis; Ticlopidine; Young Adult | 2014 |
The influence of the CYP2C19*10 allele on clopidogrel activation and CYP2C19*2 genotyping.
Topics: Alleles; Aryl Hydrocarbon Hydroxylases; Catalysis; Chromatography, Liquid; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Humans; Kinetics; Mephenytoin; Omeprazole; Pharmacogenetics; Polymorphism, Single Nucleotide; Sequence Analysis, DNA; Tandem Mass Spectrometry; Ticlopidine | 2014 |
The clopidogrel conundrum.
Topics: Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Drug Interactions; Esomeprazole; Genotype; Humans; Omeprazole; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Proton Pump Inhibitors; Ticlopidine; Treatment Outcome | 2014 |
Comparative risk of ischemic stroke among users of clopidogrel together with individual proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Brain Ischemia; Clopidogrel; Data Interpretation, Statistical; Drug Therapy, Combination; Esomeprazole; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proportional Hazards Models; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Risk; Stroke; Ticlopidine | 2015 |
The budget impact of using enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg to prevent recurrent cardiovascular events.
Topics: Adult; Aged; Aspirin; Budgets; Cardiovascular Diseases; Clopidogrel; Drug Combinations; Female; Gastrointestinal Diseases; Humans; Male; Markov Chains; Medication Adherence; Middle Aged; Models, Econometric; Omeprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Secondary Prevention; Ticlopidine | 2017 |
Drug interaction: Clopidogrel and PPIs.
Topics: Clopidogrel; Drug Interactions; Esomeprazole; Humans; Omeprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Risk Factors; Ticlopidine | 2017 |
Decrease in Switches to 'Unsafe' Proton Pump Inhibitors After Communications About Interactions with Clopidogrel.
Topics: Aged; Clopidogrel; Drug Interactions; Female; Histamine H2 Antagonists; Humans; Male; Middle Aged; Omeprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Ticlopidine | 2017 |
A pharmacokinetic model of drug-drug interaction between clopidogrel and omeprazole at CYP2C19 in humans.
Topics: Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Humans; Omeprazole; Ticlopidine | 2017 |
Interaction of CYP2C19 G681A polymorphism and omeprazole on clopidogrel responsiveness and impact in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Cross-Sectional Studies; Cytochrome P-450 CYP2C19; Drug Interactions; Female; Humans; Logistic Models; Male; Middle Aged; Omeprazole; Pharmacogenomic Testing; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Proton Pump Inhibitors; ROC Curve; Thailand; Treatment Outcome | 2020 |
Antiaggregation effect of clopidogrel in coronary heart disease patients using omeprazole.
Topics: Adult; Anti-Ulcer Agents; Clopidogrel; Coronary Disease; Female; Humans; Male; Middle Aged; Omeprazole; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Treatment Outcome; Young Adult | 2020 |
Omeprazole-clopidogrel interaction and neurovascular complications after flow-diverter device placement.
Topics: Blood Platelets; Clopidogrel; Humans; Omeprazole; Platelet Aggregation Inhibitors; Retrospective Studies | 2022 |
Study on the Interaction between Deuterium Clopidogrel and Omeprazole.
Topics: Clopidogrel; Cytochrome P-450 CYP2C19; Deuterium; Drug Interactions; Drug Therapy, Combination; Humans; Isoenzymes; Omeprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Tandem Mass Spectrometry; Ticlopidine | 2022 |
Structural characterization of the optical isomers esomeprazole and omeprazole using the JADER and FAERS databases.
Topics: Adverse Drug Reaction Reporting Systems; Cilostazol; Clopidogrel; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Esomeprazole; Hemorrhage; Humans; Omeprazole; Prasugrel Hydrochloride; United States | 2023 |
CYP2C19 loss-of-function alleles and use of omeprazole or esomeprazole increase the risk of cardiovascular outcomes in patients using clopidogrel.
Topics: Alleles; Clopidogrel; Cytochrome P-450 CYP2C19; Esomeprazole; Genotype; Humans; Omeprazole; Platelet Aggregation Inhibitors; Prospective Studies; Stroke; Treatment Outcome | 2023 |